TP53 and small cell lung carcinoma: We have developed a vaccine consisting of DCs transfected with the wild-type TP53 gene using an adenoviral vector (Ad.p53 DC vaccine), and the results of our phase II clinical trial designed to test the safety and preliminary efficacy of the Ad.p53 DC vaccine in patients with extensive-stage SCLC were published [20, 21].